This trial studies pembrolizumab, an immunotherapy drug, in HIV patients with hard-to-treat cancers. The drug helps the immune system attack cancer cells by blocking a protein that stops the immune response. Pembrolizumab has shown efficacy in various cancers, including melanoma, lung cancer, and head and neck cancer. The goal is to see if it is safe and effective for these patients.